The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 7, 1996, Pages 1711-1714

  Kew, Yvonne ^a   Salomon, Horacio ^b   Olsen, Laurence R ^a   Wainberg, Mark A ^b   Prasad, Vinayaka R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; TIBO R 82150; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BINDING SITE; CELL CULTURE; CROSS RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0030006621     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.7.1711     Document Type: Article

References (36)

1. Balzarini, J., A. Karlsson, M.-J. Perez-Perez, L. Vrang, J. Walbers, H. Zhang, B. Oberg, A.-M. Vandamme, M.-J. Camarasa, and E. De Clercq. 1993. HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192:246-253.
2. Balzarini, J., A. Karlsson, V. Sardana, E. Emini, M. J. Camarasa, and E. De Clercq. 1994. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K) RT HIV-1 mutants or select for highly resistant (Y181C→C181I) RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 91:6599-6603.
3. Balzarini, J., A. Karlsson, A.-M. Vandamme, M.-J. Perez-Perez, H. Zhang, L. Vrang, B. Oberg, K. Backbro, T. Unge, A. San-Felix, S. Velazquez, M.-J. Camarasa, and E. De Clercq. 1993. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)]-β- D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1 specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:6952-6956.
4. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
5. Buyer, P. L., C. Tantillo, A. Jacobo-Molina, R. G. Nanni, J, Ding, E. Arnold, and S. H. Hughes. 1994. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA 91:4882-4886.
6. Cheng, Y.-C., G. E. Dutschman, K. F. Bastow, M. G. Sarngadharan, and R. V. C. Ting. 1987. Human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 262:2187-2189.
7. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettel, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
8. Gau, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to (-) enantiomer of the 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
9. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
10. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase of human immunodeficiency virus resistant to 2′,3′-dideoxycytidine and 2′,3′-dideoxy,3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-280.
11. Im, G. J., E. Tramantano, C. J. Gonzalez, and Y. C. Cheng. 1993. Identification of an amino acid in the human immunodeficiency virus type 1 reverse transcriptase involved in pyrophosphate binding of antiviral nucleoside triphospbate analogs and phosphonoformate. Biochem. Pharmacol. 46: 2307-2313.
12. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. J. Clark, X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus reverse transcriptase complexed with double stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
13. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, and C. S. Crumpacker. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents. Chemother. 37:1095-1101.
14. Kew, Y., Q. Song, and V. Prasad. 1994. Subunit selective mutagenesis of Glu89 residue in human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 269:15331-15336.
15. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
16. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
17. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
18. Larder, B. A., S. D. Kemp, and D. J. M. Purifoy. 1989. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad. Sci. USA 86:4803-4807.
19. Martin, J. L., J. E. Wilson, R. L. Haynes, and P. A. Furman. 1993. Mechanism of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. Natl. Acad. Sci. USA 90:6135-6139.
20. Mellors, J., H. Bazmi, R. Schinazi, B. Roy, Y. Hsiou, E. Arnold, J. Weir, and D. Mayers. 1995. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob. Agents Chemother. 39:1087-1092.
21. Mitsuya, H., and S. Broder. 1987. Strategies for antiviral therapy in AIDS. Nature (London) 325:773-778.
22. Mitsuya, H., R. Yarchoan, and S. Broder. 1990. Molecular targets for AIDS therapy. Science 249:1533-1544.
23. Prasad, V. R., I. Lowy, T. De Los Santos, L. Chiang, and S. P. Goff. 1991. Isolation and characterization of a dideoxyguanosine triphosphate-resistant HIV-1 reverse transcriptase expressed in bacteria. Proc. Natl. Acad. Sci. USA 88:11363-11367.
24. Richman, D., C.-K. Shin, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
25. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
26. Rittinger, K., G. Divita, and R. S. Goody. 1995. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 92:8046-8049.
27. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragnei, W. A. Meyer III, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merrigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
28. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
29. Shirasaka, T., R. Yarchoan, M. C. O'Brien, R. N. Husson, B. D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
30. 89 residue in human immunodeficiency virus type 1 (HIV-1) and HIV-2 reverse transcriptases: effects on nucleoside analog resistance. J. Virol. 66:7568-7571.
31. Spence, R. A., W. M. Kati, K. S. Anderson, and K. A. Johnson. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267:988-993.
32. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
33. Tachedjian, G., D. J. Hooker, A. D. Gurusinghe, H. Bazmi, N. J. Deacon, J. Mellors, C. Birch, and J. Mills. 1995. Characterization of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology 212:58-68.
34. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5666.
35. Wainberg, M. A. Unpublished data.
36. Wainberg, M. A., et al. Unpublished data.